|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM345668790 |
| 003 |
DE-627 |
| 005 |
20231226025610.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.109102
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1152.xml
|
| 035 |
|
|
|a (DE-627)NLM345668790
|
| 035 |
|
|
|a (NLM)36049600
|
| 035 |
|
|
|a (PII)S1521-6616(22)00183-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhang, Yi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Vasicine alleviates 2,4-dinitrochlorobenzene-induced atopic dermatitis and passive cutaneous anaphylaxis in BALB/c mice
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.10.2022
|
| 500 |
|
|
|a Date Revised 11.11.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Atopic dermatitis (AD), a type of skin inflammation, is associated with immune response mediated by T-helper 2 (Th2) cells, and mast cells. Vasicine is an alkaloid isolated from Adhatoda vasica, a popular Ayurvedic herbal medicine used for treating inflammatory conditions. In the present study, the anti-AD effects of vasicine were evaluated on 2,4-dinitrochlorobenzene-induced AD-like skin lesions in BALB/c mice. The potential anti-allergic effects of vasicine were also assessed using the passive cutaneous anaphylaxis (PCA) test. The results showed that the oral administration of vasicine improved the severity of AD-like lesional skin by decreasing histopathological changes and restoring epidermal thickness. Vasicine also inhibited the infiltration of mast cells in the skin and reduced the levels of pro-Th2 and Th2 cytokines as well as immunoglobulin E in the serum. Finally, vasicine inhibited the expression of pro-Th2 and Th2 cytokines in skin tissues, indicating the therapeutic potential of vasicine for AD
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Atopic dermatitis
|
| 650 |
|
4 |
|a Mast cell
|
| 650 |
|
4 |
|a Passive cutaneous anaphylaxis
|
| 650 |
|
4 |
|a Th2 cytokine
|
| 650 |
|
4 |
|a Vasicine
|
| 650 |
|
7 |
|a Alkaloids
|2 NLM
|
| 650 |
|
7 |
|a Anti-Allergic Agents
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Dinitrochlorobenzene
|2 NLM
|
| 650 |
|
7 |
|a Quinazolines
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin E
|2 NLM
|
| 650 |
|
7 |
|a 37341-29-0
|2 NLM
|
| 650 |
|
7 |
|a vasicine
|2 NLM
|
| 650 |
|
7 |
|a 6C2ZBI733P
|2 NLM
|
| 700 |
1 |
|
|a Du, Wenxia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Defen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Meiling
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Qu, Lu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rao, Gaoxiong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lin, Yuping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tong, Xiaoyun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Yun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Feng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 244(2022) vom: 01. Nov., Seite 109102
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:244
|g year:2022
|g day:01
|g month:11
|g pages:109102
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.109102
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 244
|j 2022
|b 01
|c 11
|h 109102
|